CLAIMS

1. A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug and HPMCAS, said dispersion providing a maximum concentration of said drug in a use environment that is higher by a factor of at least 1.5 relative to a control composition comprising an equivalent quantity of undispersed drug.

2. A composition as decribed in claim 1, wherein said drug has a dose to aqueous solubility ratio greater than 100.

3. A composition as defined in claim 1, wherein said drug is crystalline when undispersed.

4. A composition as defined in claim 1, wherein said drug is amorphous when undispersed.

5. A composition as defined in claim 1, wherein said use environment is the gastrointestinal tract.

6. A composition as defined in claim 1, wherein said use environment is MFD.

7. A composition of matter comprising a spray-dried solid dispersion, which dispersion comprises a sparingly soluble drug and HPMCAS, said dispersion exhibiting a maximum supersaturated concentration in MFD which is higher by a factor of at least 1.5 relative to the equilibrium concentration exhibited by a control composition comprising an equivalent quantity of undispersed drug.

8. A composition as decribed in claim 7, wherein said drug has a dose to aqueous solubility ratio greater than 100.

9. A composition as defined in claim 7, wherein said drug is crystalline when undispersed.

10. A composition as defined in claim 7, wherein said drug is amorphous when undispersed.

11. A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug and HPMCAS, said dispersion effecting, *in vivo*, a maximal observed blood drug concentration (C_{max}) that is higher by a factor of at least 1.25 relative to a control composition comprising an equivalent quantity of undispersed drug.

12. A composition as defined in claim 11, wherein said drug is crystalline when undispersed.

13. A composition as defined in claim 11, wherein said drug is amorphous when undispersed.

14. A composition as decribed in claim 11, wherein said drug has a dose to aqueous solubility ratio greater than 100.

15. A composition comprising a spray dried solid dispersion, which dispersion comprises a sparingly water-soluble drug and HPMCAS, said dispersion effecting, *in vivo*, an AUC that is higher by a factor of at least 1.25 relative to a control composition comprising an equivalent quantity of undispersed drug.

16. A composition as defined in claim 15, wherein said drug is crystalline when undispersed.

17. A composition as defined in claim 15, wherein said drug is amorphous when undispersed.

18. A composition as decribed in claim 15, wherein said drug has a dose to aqueous solubility ratio greater than 100.

19. A process for making a spray dried solid dispersion comprising

A. forming a solution comprising (i) HPMCAS, (ii) a sparingly water-soluble drug, and (iii) a solvent in which both (i) and (ii) are soluble; and

B. spray drying said solution, thereby forming spray dried particles having an average diameter less than 100 μm.

20. A process as defined in claim 19, wherein the concentration of drug in said solvent is less than 20g/100g of solvent.

21. A process as defined in claim 19, wherein the spray drying is conducted under conditions whereby said droplets solidify in less than 20 seconds.

22. A composition as defined in claim 1, wherein the concentration of drug in MFD falls to no less than 25% of the maximum supersaturated concentration during the 15 minutes following the time at which the maximum supersaturated concentration is reached.

23. A composition as defined in claim 1, wherein said dispersion is in the form of particles less than 100 μm in diameter.

24. A composition as defined in claim 1, wherein said dispersion is in the form of particles less than 100 μm in diameter.

25. A composition as defined in claim 11, wherein said dispersion is in the form of particles less than 100 μm in diameter.

26. A composition as defined in claim 15, wherein said dispersion is in the form of particles less than 100 μm in diameter.

27. A composition as defined in claim 1, wherein the drug to HPMCAS weight ratio is from 1/0.2 to 1/100.

28. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is a glycogen phosphorylase inhibitor.

29. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is



or a pharmaceutically acceptable salt thereof.

30. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is



or a pharmaceutically acceptable salt thereof.

31. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is a 5-lipoxygenase inhibitor.

32. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is



or a pharmaceutically acceptable salt thereof.

33. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is a CRH inhibitor.

34. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is



or a pharmaceutically acceptable salt thereof.

35. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is



or a pharmaceutically acceptable salt thereof.

36. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is an antipsychotic.

37. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is ziprasidone.

38. A composition as defined in claims 1, 7, 11, or 15, wherein said compound is selected from griseofulvin, nifedipine, and phenytoin.